Literature DB >> 18032489

Species-specific restriction of apobec3-mediated hypermutation.

Edward P Browne1, Dan R Littman.   

Abstract

Apobec proteins are a family of cellular cytidine deaminases, among which several members have been shown to have potent antiviral properties. This antiviral activity is associated with the ability to cause hypermutation of retroviral cDNA. However, recent research has indicated that Apobec proteins are also able to inhibit retroviruses by other mechanisms that are independent of their deaminase activity. We have compared the antiviral activities of human and murine Apobec3 (A3) proteins, and we have found that, consistent with previous reports, human immunodeficiency virus (HIV) is able to resist human A3G but is sensitive to murine A3, whereas murine leukemia virus (MLV) is relatively resistant to murine A3 (mA3) but sensitive to human A3G. In contrast to previous studies, we observed that mA3 is packaged efficiently into MLV particles. The C-terminal cytidine deaminase domain (CDD2) is required for packaging of mA3 into MLV particles, and packaging did not depend on the MLV viral RNA. However, mA3 packed into MLV particles failed to cause hypermutation of viral DNA, indicating that its deaminase activity is blocked or inhibited. hA3G also caused significantly less hypermutation of MLV than of HIV DNA. Both mA3 and the splice variant mA3Delta5 exhibited some residual antiviral activity against MLV and caused a reduction in the ability of MLV particles to generate reverse transcription products. These results suggest that MLV has evolved specific mechanisms to block the ability of Apobec proteins to mediate deaminase-dependent hypermutation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032489      PMCID: PMC2224457          DOI: 10.1128/JVI.01371-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Yiliang Yang; Robert J Gorelick; Lawrence Kleiman
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  APOBEC3 inhibits mouse mammary tumour virus replication in vivo.

Authors:  Chioma M Okeoma; Nika Lovsin; B Matija Peterlin; Susan R Ross
Journal:  Nature       Date:  2007-01-28       Impact factor: 49.962

3.  Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Authors:  Ya-Lin Chiu; Vanessa B Soros; Jason F Kreisberg; Kim Stopak; Wes Yonemoto; Warner C Greene
Journal:  Nature       Date:  2005-04-13       Impact factor: 49.962

4.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

5.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

6.  Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F.

Authors:  Yiliang Yang; Fei Guo; Shan Cen; Lawrence Kleiman
Journal:  Virology       Date:  2007-04-24       Impact factor: 3.616

7.  APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.

Authors:  Xiao-Yu Li; Fei Guo; Li Zhang; Lawrence Kleiman; Shan Cen
Journal:  J Biol Chem       Date:  2007-09-12       Impact factor: 5.157

8.  Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

Authors:  Kun Luo; Tao Wang; Bindong Liu; Chunjuan Tian; Zuoxiang Xiao; John Kappes; Xiao-Fang Yu
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

9.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  55 in total

1.  Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.

Authors:  Mario Perkovic; Stanislaw Schmidt; Daniela Marino; Rebecca A Russell; Benjamin Stauch; Henning Hofmann; Ferdinand Kopietz; Björn-Philipp Kloke; Jörg Zielonka; Heike Ströver; Johannes Hermle; Dirk Lindemann; Vinay K Pathak; Gisbert Schneider; Martin Löchelt; Klaus Cichutek; Carsten Münk
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

2.  Biochemical and biological studies of mouse APOBEC3.

Authors:  Smita Nair; Silvia Sanchez-Martinez; Xinhua Ji; Alan Rein
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

3.  APOBEC3-mediated hypermutation of retroviral vectors produced from some retrovirus packaging cell lines.

Authors:  A D Miller; M J Metzger
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

4.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

5.  Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove.

Authors:  Bradley Sanville; Michael A Dolan; Kurt Wollenberg; Yuhe Yan; Carrie Martin; Man Lung Yeung; Klaus Strebel; Alicia Buckler-White; Christine A Kozak
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

6.  Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease.

Authors:  Richard Bannister; Deborah Rodrigues; Edward J Murray; Carl Laxton; Mike Westby; Helen Bright
Journal:  Virol J       Date:  2010-09-22       Impact factor: 4.099

7.  Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV.

Authors:  Kristin Stieler; Nicole Fischer
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

8.  APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription.

Authors:  Alyssa L MacMillan; Rahul M Kohli; Susan R Ross
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

9.  Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo.

Authors:  Eri Takeda; Sachiyo Tsuji-Kawahara; Mayumi Sakamoto; Marc-André Langlois; Michael S Neuberger; Cristina Rada; Masaaki Miyazawa
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

10.  Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex.

Authors:  Spyridon Stavrou; Takayuki Nitta; Swathi Kotla; Dat Ha; Kunio Nagashima; Alan R Rein; Hung Fan; Susan R Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.